1. Introduction

  1. Andrea Mozzarelli2,3 and
  2. Stefano Bettati2,3
  1. Richard B. Weiskopf

Published Online: 4 JUL 2011

DOI: 10.1002/9781119975427.ch1

Chemistry and Biochemistry of Oxygen Therapeutics: From Transfusion to Artificial Blood

Chemistry and Biochemistry of Oxygen Therapeutics: From Transfusion to Artificial Blood

How to Cite

Weiskopf, R. B. (2011) Introduction, in Chemistry and Biochemistry of Oxygen Therapeutics: From Transfusion to Artificial Blood (eds A. Mozzarelli and S. Bettati), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781119975427.ch1

Editor Information

  1. 2

    Department of Biochemistry and Molecular Biology, University of Parma, Parma, Italy

  2. 3

    National Institute of Biostructures and Biosystems, Rome, Italy

Author Information

  1. University of California, San Francisco, CA, USA

Publication History

  1. Published Online: 4 JUL 2011
  2. Published Print: 12 AUG 2011

ISBN Information

Print ISBN: 9780470686683

Online ISBN: 9781119975427

SEARCH

Keywords:

  • red blood cell (RBC) - a magnificently engineered apparatus;
  • regulatory criteria for blood, RBC approval - not addressing efficacy or safety;
  • red-cell efficacy – never having been, condition for regulatory approval;
  • safety, never being a condition for FDA approval - for unmodified blood, or red cells;
  • red-cell transfusion, risks - disease transmission, transfusion-associated lung injury (TRALI);
  • RBC changes, with storage - no clinical safety implications;
  • transfusion issues - and alternative approaches;
  • clinical development, non-red-cell oxygen carriers - real, perceived issues of safety;
  • Hb concentration and augmentation, not transfusing RBCs - inadequate tissue oxygenation;
  • NIH/FDA conference and symposium - formal analysis of HBOC risk, by patient age

Summary

This chapter contains sections titled:

  • References